{"id":390331,"date":"2019-11-11T00:00:00","date_gmt":"2019-11-11T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0009-2019-biopharma-ulcerative-colitis-disease-landscape-and-forecast-g7-2019\/"},"modified":"2026-04-22T23:26:19","modified_gmt":"2026-04-22T23:26:19","slug":"dlsfim0009-2019-biopharma-ulcerative-colitis-disease-landscape-and-forecast-g7-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0009-2019-biopharma-ulcerative-colitis-disease-landscape-and-forecast-g7-2019\/","title":{"rendered":"Ulcerative Colitis | Disease Landscape and Forecast | G7 | 2019"},"content":{"rendered":"<p>The ulcerative colitis (<abbr title=\"ulcerative colitis\">UC<\/abbr>) market is expected to grow steadily over the next decade. The entry of first-in-<abbr title=\"ulcerative colitis\">UC<\/abbr>\u00a0oral therapies (e.g., Pfizer\u2019s Xeljanz) for the moderate to severe population, together with additional emerging agents with novel\u00a0<abbr title=\"mechanism of action\">MOA<\/abbr>s and a general increase in the use of biologics, will help to drive market growth. In particular, the availability of non-<abbr title=\"tumor necrosis factor\">TNF<\/abbr>\u00a0biologics (e.g., Takeda\u2019s Entyvio) expands physicians\u2019 treatment armamentarium and intensifies market competition. In balance with these factors, the entry of generics for leading branded conventional agents (e.g., Shire\u2019s Lialda), continuing generic erosion of other conventional agents, and additional entries\/expanded uses of less expensive biosimilar\u00a0<abbr title=\"tumor necrosis factor\">TNF<\/abbr>-alpha inhibitors (e.g., Pfizer\u2019s Inflectra, Amgen\u2019s Amjevita) will constrain the\u00a0<abbr title=\"ulcerative colitis\">UC<\/abbr>\u00a0market. Indeed, emerging therapies looking to penetrate this market will need to be clearly differentiated from competitors.<\/p>\n<p>QUESTIONS ANSWERED<\/p>\n<ul>\n<li>What are the similarities and differences in how U.S., European, and Japanese gastroenterologists treat\u00a0<abbr title=\"ulcerative colitis\">UC<\/abbr>?<\/li>\n<li>How do gastroenterologists perceive biosimilar agents, and what impact have\/will these agents have on the\u00a0<abbr title=\"ulcerative colitis\">UC<\/abbr>\u00a0market?<\/li>\n<li>What are\u00a0<abbr title=\"key opinion leader\">KOL<\/abbr>s\u2019 insights into current treatment options (e.g., AbbVie\/Eisai\u2019s Humira, Pfizer\u2019s Xeljanz)? What factors drive their treatment decisions?<\/li>\n<li>What are\u00a0<abbr title=\"key opinion leader\">KOL<\/abbr>s\u2019 perceptions of key emerging therapies (e.g., AbbVie\u2019s upadacitinib, Roche\/Genentech\u2019s etrolizumab, Janssen\u2019s Stelara, Celgene\u2019s ozanimod), and where do they see these agents fitting into the treatment algorithm?<\/li>\n<\/ul>\n<p>PRODUCT DESCRIPTION<\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390331","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-ulcerative-colitis","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390331","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390331\/revisions"}],"predecessor-version":[{"id":576589,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390331\/revisions\/576589"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390331"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}